Skip to content
Biotechnology, Results Statistics

Powerball Draw no. 1463

The Lottery Corporation Ltd < 1 mins read

Official Results

 

Powerball Draw no. 1463

Draw Date: Thursday, 30 May 2024

 

 

 


Drawn Numbers

Winning Numbers

 

35

2

3

33

20

22

10

(drawn order)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Powerball

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


               Dividends

 

Dividends

Total Winners

Total Prizes Payable

 

 

 

 

Division 1

$0.00

0

$0.00

Division 2

$270,217.65

1

$270,217.65

Division 3

$9,598.45

35

$335,945.75

Division 4

$571.70

511

$292,138.70

Division 5

$192.00

1,141

$219,072.00

Division 6

$79.50

17,268

$1,372,806.00

Division 7

$49.50

21,547

$1,066,576.50

Division 8

$20.30

111,436

$2,262,150.80

Division 9

$11.90

326,742

$3,888,229.80

 

 

 

 

 

 

478,681

$9,707,137.20

Division 1 Jackpots to $12,000,000.00

 

 

 

 

 

Media

More from this category

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

  • Biotechnology
  • 10/12/2025
  • 10:19
OncoSil Medical Limited (ASX:OSL)

First OncoSil treatment in United Kingdom

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital SouthamptonNHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.